Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.810
-0.020 (-1.09%)
At close: Apr 20, 2026, 4:00 PM EDT
1.810
0.00 (0.00%)
After-hours: Apr 20, 2026, 4:10 PM EDT
Inhibikase Therapeutics Employees
Inhibikase Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 19 or 118.75% compared to the previous year.
Employees
35
Change (1Y)
19
Growth (1Y)
118.75%
Revenue / Employee
n/a
Profits / Employee
-$1,378,834
Market Cap
308.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 19 | 118.75% | 35 | 0 |
| Dec 31, 2024 | 16 | 7 | 77.78% | 15 | 1 |
| Dec 31, 2023 | 9 | 2 | 28.57% | 8 | 1 |
| Dec 31, 2022 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2021 | 7 | 4 | 133.33% | 6 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Abeona Therapeutics | 226 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Zentalis Pharmaceuticals | 106 |
| Artiva Biotherapeutics | 104 |
IKT News
- 13 days ago - Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire
- 17 days ago - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 8 months ago - Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - GlobeNewsWire